利拉鲁肽联合胰岛素对控制不佳的2型糖尿病疗效的回顾性分析

叶 正华¹, 叶 晖²
1、武汉市第一医院内分泌科
2、北京大学第一医院中西医结合科

摘要

目的初步分析利拉鲁肽联合胰岛素治疗2型糖尿病的疗效和作用特点。方法回顾性收集2017年1月至2017年12月武汉市第一医院内分泌科因血糖控制不佳入院且采用利拉鲁肽 胰岛素或胰岛素治疗的患者，比较两组治疗前后空腹及三餐后血糖水平。结果利拉鲁肽 胰岛素组平均住院日9.77±1.99天，空腹血糖由10.13±3.77mmol/L下降至7.32±1.51mmol/L，早餐后血糖由14.33±3.7mmol/L下降至8.19±2.10 mmol/L，午餐后血糖由13.97±4.44mmol/L下降至9.12±2.45 mmol/L，晚餐后血糖由12.80±3.20mmol/L下降至8.65±2.11 mmol/L，治疗前后均有统计学差异；胰岛素组空腹血糖由9.70±3.23mmol/L下降至7.31±2.08mmol/L，早餐后血糖由15.79±3.88mmol/L下降至9.76±3.96mmol/L，午餐后血糖由12.98±5.05mmol/L下降至10.84±3.12mmol/L，晚餐后血糖由12.30±4.12mmol/L下降至9.59±3.79mmol/L。结论在相同的住院时间内，利拉鲁肽联合胰岛素更为有效地控制餐后血糖水平。

关键词

利拉鲁肽；胰岛素；2型糖尿病；回顾性研究

参考

[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中华糖尿病杂志,2018,10(1):4-67. [2]Ali MK,Bullard KM,Saaddine JB,et al.Achievement of goals in U.S. diabetes care,1999–2010[J].N Engl J Med,2013(368):1613-1624. [3]Peyrot M,Rubin RR,Khunti K.Addressing barriers to initiation of insulin in patients with type 2 diabetes[J].Prim Care Diabetes,2010(4):11-18. [4]Nauck MA,Meier JJ.The incretin effect in healthy individuals and those with type 2 diabetes:physiology,pathophysiology, and response to therapeutic interventions[J].Lancet Diabetes Endocrinol,2016(4):525-536. [5]Pratley RE.Overview of glucagon‐like peptide‐1 analogs and dipeptidyl peptidase‐4 inhibitors for type 2 diabetes[J].Medscape J Med,2008(10):171. [6]Hyun Jin Kim,Seok O Park,Seung-Hyun Ko,et al.Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association[J].Diabetes Metab J,2017(41):423-429. [7]张敏,叶茂,于静.利拉鲁肽的分子结构及其药理作用[J].湖北民族学院学报·医学版,2011,28(1):67-70. [8]Kela R,Davies MJ.Treatment evaluation of liraglutide in type 2 diabetes[J].Expert OpinBiol Ther,2012(12):1551-1556. [9]Calvo Gómez C,Gómez-Huelgas R,Lima Ruiz J,et al.Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine[J].Int J ClinPharmacolTher,2016,54(11):880-890. [10]Guthrie R.Practice pearl:liraglutide and cardiovascular and renal events in type 2 diabetes[J].Postgrad Med,2018,130(2):154-158. [11]Flint A,Kapitza C,Hindsberger C,etal.The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients[J].AdvTher,2011,28(3):213-226. [12]MitsuyoshiTakahara,Toshihiko Shiraiwa, KentaroOhtoshi, et al. Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy[J].J Diabetes Investig,2012,3(6):510-516.